Holen Sie sich die Stockscreener-App
0.9655
3.48%
0.0325
Schlusskurs vom Vortag:
$0.933
Offen:
$0.95
24-Stunden-Volumen:
82,766
Relative Volume:
0.26
Marktkapitalisierung:
$3.78M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-9.34M
KGV:
-0.1352
EPS:
-7.14
Netto-Cashflow:
$-6.69M
1W Leistung:
+2.71%
1M Leistung:
+3.42%
6M Leistung:
-52.79%
1J Leistung:
-67.82%
1-Tages-Spanne:
$0.93
$0.98
1-Wochen-Bereich:
$0.8658
$1.21
52-Wochen-Spanne:
$0.801
$16.63
Painreform Ltd Stock (PRFX) Company Profile
Vergleichen Sie PRFX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRFX
Painreform Ltd
|
0.9655 | 3.65M | 0 | -9.34M | -6.69M | -7.14 |
|
ZTS
Zoetis Inc
|
118.07 | 51.01B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.37 | 45.05B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.46 | 41.46B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.80 | 32.77B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
484.86 | 20.51B | 3.08B | 1.24B | 1.07B | 25.61 |
Painreform Ltd Aktie (PRFX) Neueste Nachrichten
PainReform completed R&D assessment of LayerBio’s drug-delivery platform - TipRanks
PainReform’s LayerBio Platform Advances with Multi-Drug Capability - TipRanks
PainReform Ltd. Completes R&D Assessment of LayerBio's Sustained-Release Ocular Drug-Delivery Platform - Quiver Quantitative
PainReform (Nasdaq: PRFX) validates LayerBio drop-less ocular platform for multi-drug cataract care - Stock Titan
PainReform Ltd. (PRFX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
PainReform commences development plan for OcuRing-K Phase II trial - MSN
Is PainReform Ltd (PRFX) positioned for future growth? - Setenews
Will PainReform Ltd. stock pay special dividendsPortfolio Profit Report & Growth Oriented Trade Recommendations - Newser
Will PainReform Ltd. stock maintain dividend yieldMarket Volume Summary & Stock Portfolio Risk Management - Newser
PainReform Ltd. Commences Development for OcuRing??-K Phase II Trial, LayerBio's Drop-Less Sustained-Release Ocular Therapy - marketscreener.com
PainReform begins development plan for drop-less cataract surgery therapy By Investing.com - Investing.com
PainReform (PRFX) Advances OcuRing-K Development for Improved Ca - GuruFocus
PainReform Initiates Phase II Development for OcuRing™-K - TipRanks
Painreform commences development for Ocuring-K phase II trial - marketscreener.com
PainReform begins development plan for drop-less cataract surgery therapy - Investing.com
PainReform (Nasdaq: PRFX) moves OcuRing-K into Phase II plan in $9B cataract market - Stock Titan
PainReform Ltd. (PRFX) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
What drives PainReform Ltd stock priceTake Profit Strategies & Free High Profit Capital Plays - earlytimes.in
PainReform’s DeepSolar Advances with NVIDIA Connect and Pilot Projects - MSN
Can PainReform Ltd. stock deliver sustainable ROEJuly 2025 Price Swings & Daily Growth Stock Investment Tips - moha.gov.vn
Is PainReform Ltd. stock attractive for income investorsWeekly Profit Summary & Daily Growth Stock Tips - BỘ NỘI VỤ
PainReform schedules annual shareholder meeting for December 30 in Tel Aviv - Investing.com
PainReform Ltd. Announces December 2025 Shareholders Meeting with Key Proposals - TipRanks
Longview Tea Company Limited Stock Analysis Technical Signals for 2025High Beta Stocks & Small Investment Capital Tips - earlytimes.in
Is PainReform Ltd. stock recession proofQuarterly Profit Report & Advanced Swing Trade Entry Alerts - newser.com
Is PainReform Ltd. stock cheap at current valuationJuly 2025 Movers & Smart Swing Trading Techniques - newser.com
Will PainReform Ltd. bounce back from current supportEarnings Overview Summary & AI Driven Stock Movement Reports - newser.com
Price momentum metrics for PainReform Ltd. explainedMarket Performance Recap & Daily Technical Stock Forecast Reports - newser.com
Is PainReform Ltd. stock attractive for long term wealth buildingWeekly Gains Report & Expert Approved Trade Ideas - newser.com
PainReform (NASDAQ:PRFX) Trading Down 1.3% – Here’s Why - Defense World
How PainReform Ltd. stock compares to industry benchmarksEarnings Risk Summary & Technical Buy Zone Confirmation - newser.com
Why PainReform Ltd. stock could rally in 2025Weekly Trade Review & Verified Technical Signals - newser.com
Best data tools to analyze PainReform Ltd. stockAnalyst Downgrade & Daily Price Action Insights - newser.com
symbol__ Stock Quote Price and Forecast - CNN
PainReform’s DeepSolar Advances AI Reporting Engine for Solar Assets - MSN
PainReform (PRFX) Unveils Automated Reporting Engine for Solar P - GuruFocus
PainReform’s DeepSolar Advances Development of its AI-Driven Automated Reporting Engine for Solar-Asset Analysis - The Manila Times
[6-K] PAINREFORM LTD. Current Report (Foreign Issuer) | PRFX SEC FilingForm 6-K - Stock Titan
Finanzdaten der Painreform Ltd-Aktie (PRFX)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.87%
4.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):